RAD9A
Basic information
Region (hg38): 11:67317871-67398410
Previous symbols: [ "RAD9" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the RAD9A gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 21 | 23 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 21 | 2 | 0 |
Variants in RAD9A
This is a list of pathogenic ClinVar variants found in the RAD9A region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-67352011-T-C | not specified | Uncertain significance (Mar 15, 2024) | ||
11-67352749-G-T | not specified | Uncertain significance (Dec 13, 2022) | ||
11-67352793-C-A | not specified | Uncertain significance (Sep 26, 2023) | ||
11-67353001-G-A | Likely benign (Jan 01, 2023) | |||
11-67353009-A-G | not specified | Uncertain significance (Aug 30, 2021) | ||
11-67353345-C-T | not specified | Uncertain significance (Sep 06, 2022) | ||
11-67353365-G-A | not specified | Uncertain significance (Oct 26, 2022) | ||
11-67353371-G-C | not specified | Uncertain significance (Mar 31, 2024) | ||
11-67365138-A-G | Cold-induced sweating syndrome 2 | Pathogenic (Jun 15, 2010) | ||
11-67365147-GAGCCCCC-G | not specified | Benign (May 20, 2022) | ||
11-67365215-T-C | not specified | Uncertain significance (Jun 07, 2024) | ||
11-67365221-G-A | not specified | Uncertain significance (Oct 05, 2021) | ||
11-67365224-C-A | Cold-induced sweating syndrome 2 | Pathogenic (Jun 27, 2006) | ||
11-67365265-G-A | CLCF1-related disorder | Likely benign (May 25, 2019) | ||
11-67365327-G-A | not specified | Uncertain significance (Mar 28, 2024) | ||
11-67365366-C-T | not specified | Uncertain significance (Apr 07, 2022) | ||
11-67365422-C-T | not specified | Uncertain significance (Jun 29, 2022) | ||
11-67365425-C-T | not specified | Uncertain significance (Sep 16, 2021) | ||
11-67365426-G-A | not specified | Uncertain significance (Jan 23, 2024) | ||
11-67365427-C-T | Likely benign (Aug 16, 2018) | |||
11-67365450-G-C | not specified | Uncertain significance (Mar 20, 2024) | ||
11-67365456-G-A | not specified | Uncertain significance (Dec 11, 2023) | ||
11-67365493-G-T | Cold-induced sweating syndrome 2 | Pathogenic (Jun 27, 2006) | ||
11-67365521-T-C | not specified | Uncertain significance (May 30, 2024) | ||
11-67365523-G-A | Likely benign (Dec 31, 2019) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
RAD9A | protein_coding | protein_coding | ENST00000307980 | 11 | 6706 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00000403 | 0.839 | 125717 | 0 | 30 | 125747 | 0.000119 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.00665 | 246 | 246 | 1.00 | 0.0000153 | 2512 |
Missense in Polyphen | 77 | 91.028 | 0.84589 | 990 | ||
Synonymous | -1.96 | 127 | 102 | 1.25 | 0.00000622 | 809 |
Loss of Function | 1.41 | 11 | 17.3 | 0.635 | 7.35e-7 | 211 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000482 | 0.000428 |
Ashkenazi Jewish | 0.0000993 | 0.0000992 |
East Asian | 0.000112 | 0.000109 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000132 | 0.000132 |
Middle Eastern | 0.000112 | 0.000109 |
South Asian | 0.000131 | 0.000131 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Component of the 9-1-1 cell-cycle checkpoint response complex that plays a major role in DNA repair. The 9-1-1 complex is recruited to DNA lesion upon damage by the RAD17-replication factor C (RFC) clamp loader complex. Acts then as a sliding clamp platform on DNA for several proteins involved in long-patch base excision repair (LP-BER). The 9-1-1 complex stimulates DNA polymerase beta (POLB) activity by increasing its affinity for the 3'-OH end of the primer-template and stabilizes POLB to those sites where LP-BER proceeds; endonuclease FEN1 cleavage activity on substrates with double, nick, or gap flaps of distinct sequences and lengths; and DNA ligase I (LIG1) on long-patch base excision repair substrates. The 9-1-1 complex is necessary for the recruitment of RHNO1 to sites of double-stranded breaks (DSB) occurring during the S phase. RAD9A possesses 3'->5' double stranded DNA exonuclease activity. Its phosphorylation by PRKCD may be required for the formation of the 9-1-1 complex. {ECO:0000269|PubMed:10713044, ECO:0000269|PubMed:21659603}.;
- Pathway
- Cellular senescence - Homo sapiens (human);Androgen receptor signaling pathway;miRNA Regulation of DNA Damage Response;ATM Signaling Pathway;ATR Signaling;DNA IR-Double Strand Breaks (DSBs) and cellular response via ATM;DNA Damage Response;HDR through Single Strand Annealing (SSA);HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA);DNA Repair;Gene expression (Transcription);DNA Double-Strand Break Repair;role of brca1 brca2 and atr in cancer susceptibility;Generic Transcription Pathway;Homology Directed Repair;RNA Polymerase II Transcription;G2/M DNA damage checkpoint;Activation of ATR in response to replication stress;G2/M Checkpoints;Cell Cycle Checkpoints;Fanconi anemia pathway;Regulation of TP53 Activity through Phosphorylation;Regulation of TP53 Activity;Transcriptional Regulation by TP53;Cell Cycle;Regulation of Telomerase;Processing of DNA double-strand break ends;ATM pathway;ATR signaling pathway;Presynaptic phase of homologous DNA pairing and strand exchange;Homologous DNA Pairing and Strand Exchange;HDR through Homologous Recombination (HRR)
(Consensus)
Recessive Scores
- pRec
- 0.197
Intolerance Scores
- loftool
- 0.588
- rvis_EVS
- -0.33
- rvis_percentile_EVS
- 30.7
Haploinsufficiency Scores
- pHI
- 0.511
- hipred
- Y
- hipred_score
- 0.740
- ghis
- 0.534
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.972
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Rad9a
- Phenotype
- homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); pigmentation phenotype; neoplasm; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Gene ontology
- Biological process
- DNA replication checkpoint;DNA damage checkpoint;DNA repair;cellular response to DNA damage stimulus;intra-S DNA damage checkpoint;cellular response to ionizing radiation;nucleic acid phosphodiester bond hydrolysis;positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage
- Cellular component
- nucleus;nucleoplasm;cytoplasm;checkpoint clamp complex
- Molecular function
- protein binding;3'-5' exonuclease activity;exodeoxyribonuclease III activity;SH3 domain binding;enzyme binding;protein kinase binding;histone deacetylase binding